Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma

Rogers, Jane E.; Jácome, Alexandre A. A.; Ohinata, Aki; Wolff, Robert A.; Morris, Van K.; Johnson, Benny; Mehdizadeh, Amir; Rothschild, Nicole D.; Ahmed, Shahab; Guerra, Jennifer L.; Eng, Cathy

doi:10.1080/14737140.2020.1810573

Cited by 8 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one single-institution series, the disease control was 55%. 60,61,114 Future clinical trials should elucidate the efficacy of this approach in combination with other targeted agents.…”

Section: Treatment For Metastatic Anal Cancermentioning

confidence: 99%

Anal Cancer: Emerging Standards in a Rare Disease

Eng

Ciombor

Cho

et al. 2022

JCO

Self Cite

View full text Add to dashboard Cite

The social stigma surrounding an anal cancer diagnosis has traditionally prevented open discussions about this disease. However, as recent treatment options and an increasing rate of diagnoses are made worldwide, awareness is growing. In the United States alone, 9,090 individuals were expected to be diagnosed with anal cancer in 2021. The US annual incidence of squamous cell carcinoma of the anus continues to increase by 2.7% yearly, whereas the mortality rate increases by 3.1%. The main risk factor for anal cancer is a human papillomavirus infection; those with chronic immunosuppression are also at risk. Patients with HIV are 19 times more likely to develop anal cancer compared with the general population. In this review, we have provided an overview of the carcinoma of the anal canal, the role of screening, advancements in radiation therapy, and current trials investigating acute and chronic treatment–related toxicities. This article is a comprehensive approach to presenting the existing data in an effort to encourage continuous international interest in anal cancer.

show abstract

“…In one single-institution series, the disease control was 55%. 60,61,114 Future clinical trials should elucidate the efficacy of this approach in combination with other targeted agents.…”

Section: Treatment For Metastatic Anal Cancermentioning

confidence: 99%

Anal Cancer: Emerging Standards in a Rare Disease

Eng

Ciombor

Cho

et al. 2022

JCO

Self Cite

View full text Add to dashboard Cite

show abstract

“…While EGFR overexpression is extremely common in SCCA in up to 88% of cases, the EGFR mutation rates were found to be very low across multiple studies [52,66,[70][71][72]. In a study with a small sample of 56 patients, most of the patients (approximately 90%) received anti-EGFR monoclonal antibodies with chemotherapy, and the response rate of any response was 41%, median PFS was 4.3 months and median OS was 16 months [54]. In another study of 17 patients where 76% of the patients received an EGFR monoclonal antibody in the second-line setting, 35% had an ORR and 24% had stable disease.…”

Section: Epidermal Growth Factor Receptor (Egfr)mentioning

confidence: 99%

“…The targeted treatment of EGFR has been explored due to its high expression, which was estimated to be 85% by a study utilizing immunohistochemistry in SCCA [52]. The combination of chemotherapy with EGFR inhibitors showed promising survival outcomes in a retrospective case series and in a prospective study involving patients with metastatic SCCA [53,54]. The phase II CARACAS trial studied the combination of avelumab and cetuximab in a prospective, non-comparative randomized multicenter open-label trial in patients with unresectable, locally advanced or metastatic disease with a primary end point of ORR.…”

Section: Novel Combination Of Icimentioning

confidence: 99%

Recent Advances in the Management of Anal Cancer

Upadhyay,

Hartzell,

Parikh

et al. 2023

Healthcare

View full text Add to dashboard Cite

The incidence and mortality of squamous cell carcinoma of the anus (SCCA) is on the rise, which highlights the unmet need for advances in treatment options. The landscape of treatment for this cancer is rapidly evolving with novel combination strategies including immunotherapy, radiation therapy and biomarker-guided therapy. This review article features an overview of recent advancements in both locoregional and metastatic SCCA. The recent focus on locoregional SCCA management is to tailor treatment according to tumor burden and minimize treatment-related toxicities. Mitomycin plus either infusional 5-fluorouracil (5-FU) or capecitabine is used for first-line chemoradiotherapy (CRT), and intensity-modulated radiotherapy (IMRT) is the preferred modality for radiation for locoregional anal cancer. Locally recurrent disease is managed with surgical resection. Systemic treatment is first-line for metastatic SCCA and immunotherapy with nivolumab and pembrolizumab being included as second-line agents. Current and future clinical trials are evaluating treatments for SCCA including immunotherapy alone or in combination regimens, radiotherapies, targeted treatments and novel agents. Another critical aspect of current research in SCCA is the personalization of CRT and immunotherapies based on molecular characterization and biomarkers such as the programmed death-ligand 1 (PD-L1), epidermal growth factor receptor (EGFR) and circulating tumor DNA.

show abstract

“…There are no prospective studies evaluating the role of anti-EGFR monoclonal antibodies in both localized and advanced disease. Retrospective studies suggest the efficacy of these agents in advanced SCCA, both in monotherapy and in combination with chemotherapy [ 32 , 90 , 91 , 92 ]. The randomized phase II CARACAS trial explored dual PD-1 and EGFR blockade in previously treated advanced SCCA patients.…”

Section: Biomarkersmentioning

confidence: 99%

Biomarkers in Anal Cancer: Current Status in Diagnosis, Disease Progression and Therapeutic Strategies

Mathias-Machado

Peixoto²,

Moniz

et al. 2022

Biomedicines

View full text Add to dashboard Cite

Squamous cell carcinoma of the anal canal (SCCA) is a rare neoplasm, but with rising incidence rates in the past few decades; it is etiologically linked with the human papillomavirus (HPV) infection and is especially prevalent in immunocompromised patients, mainly those infected with HIV. Fluoropyrimidine-based chemoradiotherapy remains the cornerstone of the treatment of non-metastatic disease, but the locally advanced disease still presents high rates of disease recurrence and systemic therapy of SCCA is an unmet clinical need. Despite sharing common molecular aspects with other HPV-related malignancies, such as cervical and head and neck cancers, SCCA presents specific epigenomic, genomic, and transcriptomic abnormalities, which suggest that genome-guided personalized therapies should be specifically designed for this disease. Actionable mutations are rare in SCCA and immune checkpoint inhibition has not yet been proven useful in an unselected population of patients. Therefore, advances in systemic therapy of SCCA will only be possible with the identification of predictive biomarkers and the subsequent development of targeted therapies or immunotherapeutic approaches that consider the unique tumor microenvironment and the intra- and inter-tumoral heterogeneity. In the present review, we address the molecular characterization of SCCA and discuss potential diagnostic, predictive and prognostic biomarkers of this complex and challenging disease.

show abstract

Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma

Cited by 8 publications

References 16 publications

Anal Cancer: Emerging Standards in a Rare Disease

Anal Cancer: Emerging Standards in a Rare Disease

Recent Advances in the Management of Anal Cancer

Biomarkers in Anal Cancer: Current Status in Diagnosis, Disease Progression and Therapeutic Strategies

Contact Info

Product

Resources

About